genglob magazine


magazine by for generics, medicines and alternative treatments like ayurveda and traditional chinese

Natco Pharma awarded the compulsory licence to manufacture Bayer’s cancer drug Nexavar

Natco Pharma is back in limelight after the Indian Patents Appellate Board upheld the decision of awarding compulsory license to the drug firm to manufacture Bayer’s cancer drug Nexavar at a significantly reduced price.

The Hyderabad-based drug company is engaged in formulations, active pharmaceutical ingredients ( APIs) and owns a retail pharmacy business in the US. It earns majority of its revenues from oncology drugs. Following the Indian Patent office awarding compulsory license to the company, it has been selling the generic version of Bayer’s drug Nexavar, meant for treating a rare liver and kidney cancer, since April last year. In the months from April to December last year, the company sold the drug worth Rs 14 crore and expects the revenues from this product to range between Rs 15 and 20 crore in the coming years. While the company does not earned significantly from the drug, it achieved the breakthrough of winning a compulsory license for manufacturing the generic version of a life-saving drug – opening inroads for cheaper drugs in the country. Read the rest of this entry »